Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
13.80
-1.08 (-7.26%)
At close: Mar 3, 2026, 4:00 PM EST
13.78
-0.02 (-0.14%)
After-hours: Mar 3, 2026, 7:43 PM EST
Eikon Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Eikon Therapeutics stock have a consensus rating of "Buy" and an average price target of $25.6, which forecasts a 85.51% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $34.
Price Target: $25.6 (+85.51%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Eikon Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 |
|---|---|
| Strong Buy | 1 |
| Buy | 4 |
| Hold | 0 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 2, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $29 | Buy | Initiates | $29 | +110.14% | Mar 2, 2026 |
| B of A Securities | B of A Securities | Strong Buy Initiates $34 | Strong Buy | Initiates | $34 | +146.38% | Mar 2, 2026 |
| Mizuho | Mizuho | Buy Initiates $26 | Buy | Initiates | $26 | +88.41% | Mar 2, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $32 | Buy | Initiates | $32 | +131.88% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
No data available
Revenue Growth
No data available
EPS Forecast
No data available
EPS Growth
No data available
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.